Atherosclerosis and Rheumatic DiseasesMaya Mattar, Bochra Jandali, Charles J Malemud* and Ali D Askari
Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center,Cleveland, Ohio 44016, USA
- *Corresponding Author:
- Charles J Malemud
PhD, Professor of Medicine and Anatomy
Department of Medicine, Division of Rheumatic Diseases
University Hospitals Case Medical Center
Foley Medical Building 2061 Cornell Road
Room 207, Cleveland, Ohio, 44106-5076, USA
Tel: (216) 844-7846
Fax: (216) 844-2288
E-mail: [email protected]
Received date: March 02, 2014; Accepted date: February 27, 2015; Published date: March 10, 2015
Citation: Mattar M, Jandali B, Malemud CJ, Askari AD (2015) Atherosclerosis and Rheumatic Diseases. Rheumatology (Sunnyvale) 5:147. doi:10.4172/2161-1149.1000147
Copyright: © 2015 Mattar M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Until recently, patients with chronic autoimmune diseases were dying at a young age from their disease. However, with the emergence of biologic drugs and disease-targeted therapies, longevity in this patient population has increased. In addition, physicians have become more aware of the long-term sequelae of chronic inflammation focusing mainly on the development of premature atherosclerosis. In this review we will systematically analyze the most relevant published papers for the PubMed Central database and other validated-internet sources that have relevance to the role that atherosclerosis plays in several autoimmune diseases including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). We also examined the effects of disease modifying agents on the development of atherosclerosis in patients with autoimmune diseases as well as identifying strategies or interventions which can prevent or retard the development of cardiovascular disease in these patients.